You are here

Therapeutic Advances in Urology

Therapeutic Advances in Urology


eISSN: 17562880 | ISSN: 17562872 | Current volume: 16 | Current issue: 1 Frequency: Yearly

Journal Highlights

  • Launched in 2009
  • Gold open access journal – all articles are made freely available online immediately upon publication
  • Rigorous peer review
  • Listed in PubMed and indexed in Web of Science, Science Citation Index Expanded (SCIE) and Scopus
  • Over 200,000 full-text article views annually

Therapeutic Advances in Urology (TAU) is a peer-reviewed open access journal delivering the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of urology. Please see the Aims and Scope for further information.

This journal is a member of the Committee on Publication Ethics (COPE).

This journal flipped to open access on January 1, 2019.

Diversity, Equity and Inclusion Statement

Therapeutic Advances in Urology (TAU) promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the urology community.

Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.

We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status or any other individual status.

We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms.

Submission information

Submit your manuscript today at http://mc.manuscriptcentral.com/tau.

Open access information

Publication in the journal is subject to payment of an article processing charge (APC). The APC serves to support the journal and ensures that articles are freely accessible online in perpetuity under a Creative Commons licence.

The APC for this journal is currently $3,000 USD.

The APC is payable when a manuscript is accepted after peer review, before it is published. The APC is also subject to taxes where applicable. Please see further details here.

Meet the Editorial Team

Click here to meet the Editorial Team of Therapeutic Advances in Urology (TAU).

Contact

Please direct any queries to urology@sagepub.co.uk.

Therapeutic Advances in Urology delivers the highest quality peer-reviewed, open access, original research articles, reviews, and scholarly comment on pioneering efforts across all areas of urology. The journal is aimed at an international audience of clinicians, researchers and allied health practitioners in urology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.

Therapeutic Advances in Urology covers themes including but not limited to:

  • Urologic oncology
  • Endourology
  • Andrology, Fertility and Sexual Health
  • Urogynaecology
  • Bladder disorders
  • Surgery
  • Uro-technology
  • Radiology
  • Urological education and training (including technological advances such as surgical simulation)

Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of the first patient enrolment.

Editor-in-Chief
Sanjeev Madaan, MD, PhD Darent Valley Hospital, Dartford, UK
Managing Editor
Atharva Gajanan Gajalkar SAGE Publishing, India
Gayatri More SAGE Publishing, New Delhi, India
Amy Goundry SAGE Publications Ltd, UK
Associate Editors
Fabio Crocerossa, MD, PhD Magna Graecia University of Catanzaro, Catanzaro, Italy
David Castro Díaz, MD Hospital Universitario de Canarias, Tenerife, Spain
Lawrence Jenkins, MD, MBA Tulane University, New Orleans, LA, USA
Daniel Lee, MD Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Naside Mangir, MD, PhD Hacettepe University, Ankara, Turkey
Bhaskar K. Somani, MD University Hospital Southampton NHS Trust, Southampton, UK
Endourology
Daniele Castellani, MD AOU Ospedali Riuniti di Ancona, Ancona, Italy
Jean de la Rosette, MD Istanbul Medipol University, Istanbul, Turkey
Vineet Gauhar, MD Ng Teng Fong General Hospital (NTFGH)/NUHS, Singapore, Singapore
Khurshid Ghani, MBChB, MS University of Michigan, Ann Arbor, MI, USA
A Reza Haghpanah MD ,FEBU Shiraz University of Medical Sciences, Shiraz ,Iran
Patrick Juliebø-Jones, MD Haukeland University Hospital, Bergen, Norway
Theodoros Tokas MD, PhD University of Crete, General Hospital of Heraklion, Greece
Carlos Gustavo Trujillo, MD Fundación Santa Fe de Bogotá, Bogotá, Colombia
Lazaros Tzelves, MD National and Kapodistrian University of Athens, Sismanogleio Hospital, Athens, Greece
Perry Xu MD Northwestern University School of Medicine, Chicago, IL, USA
Justin Bradley Ziemba, MD, MSEd University of Pennsylvania, Philadelphia, PA, USA
Urinary Tract Infections
Glenn Werneburg MD, PhD Cleveland Clinic, Cleveland, OH, USA
Andrology, Fertility and Sexual Health
Hussain M Alnajjar, MD University College London Hospitals NHS Trust, London, UK
Hakan Anil, MD, MSc Adana City Training and Research Hospital, Adana, Turkey
Marco Falcone, MD, PhD University of Turin, Turin, Italy
Muhammed A Moukhtar Hammad, MBBCh, MSc University of California, Irvine, CA, USA
Vaibhav Modgil, MD, MSc Manchester University NHS Foundation Trust, Manchester, UK
Darshan P Patel, MD University of California San Diego, La Jolla, CA, USA
Amy Pearlman, MD Prime Institute, Fort Lauderdale, FL, USA
Nahid Punjani, MD, MPH Mayo Clinic, Rochester, MN, USA
Urologic Oncology
Melissa Bersanelli, MD, PhD University of Parma, Parma, Italy
Francesco Cantiello, MD, PhD Magna Graecia University of Catanzaro, Catanzaro, Italy
Julian Chavarriaga, MD University of Toronto, Princess Margaret Cancer Centre, Toronto, Canada
Prantik Das, MBBS University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK
Ithaar Derweesh, MD UCSD, San Diego, California, USA
Dr Zachary Dovey, MRCP, FRCS Mount Sinai Queens and Icahn School of Medicine at The Mount Sinai Hospital, NY, USA
Herney Andres Garcia-Perdomo, MD, MSc, PhD School of Medicine, Universidad del Valle, Cali, Colombia
Saum Ghodoussipour, MD Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Ana María Autrán Gomez, MD, PhD Lyx Urology, Madrid, Spain
Vital Hevia, MD, PhD Hospital Universitario Ramón y Cajal, Madrid, Spain
Kazumasa Komura, MD, PhD Osaka Medical and Pharmaceutical University, Osaka, Japan
Haoran Li, MD, PhD University of Kansas Cancer Center, Westwood, KS, USA
Fernando Sabino Marques Monteiro MD, PhD Hospital Sírio Libanês, Brasilia, Brazil
Anirban Mitra, MBBS MD Anderson Cancer Center, Houston, TX, USA
Venkata Ramana Murthy Kusuma, MBBS Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK
Günter Niegisch, MD Heinrich Heine University Düsseldorf, Düsseldorf, Germany
Savio Domenico Pandolfo, MD, PhD University of Naples "Federico II", Naples, Italy
Giuseppe Procopio, MD Fondazione Istituto Nazionale Tumori, Milan, Italy
Sara Elena Rebuzzi, MD Ospedale San Paolo, Savona, Italy
Werner T W de Riese, MD, PhD Texas Tech University Health Sciences Center, School of Medicine, Lubbock, TX, USA
Juan Gómez Rivas, MD, PhD Hospital Clínico San Carlos, Madrid, Spain
Mimma Rizzo, MD Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy
Giandomenico Roviello, MD, PhD University of Florence, Florence, Italy
Kamal Kant Sahu, MD, MBBS Huntsman Cancer Institute, University of Utah, UT, USA
Grannum R Sant, MB BCh BAO (Hons), MD Tufts University School of Medicine, Boston, MA, USA
Anand Sharma, MD, MBBS Mount Vernon Cancer Centre, London, UK
Urogynaecology
Enrico Ammirati, MD, PhD Unità Spinale Unipolare, Turin, Italy
Elisabetta Costantini, MD, PhD University of Perugia, Perugia, Italy
Sherif Mourad, MD, PhD Ain Shams University, Cairo, Egypt
Surgery
Giancarlo Albo MD, PhD University of Milan, Milan, Italy
Riccardo Autorino, MD, PhD VCU Health, Richmond, VA, USA
Arjun K. Nambiar, MD, PhD Freeman Hospital, Newcastle-upon-Tyne, UK
Dmitriy Nikolavsky, MD SUNY Upstate Medical University, Syracuse, NY, USA
Bladder Disorders
Bertil Blok, MD, PhD Erasmus Medical Center, Rotterdam, The Netherlands
Jan Groen, MD, PhD Erasmus Medical Center, Rotterdam, The Netherlands
Arun Sahai MD, PhD Guy’s Hospital & King’s College London, London, UK
General Urology
Jeff John, MBChB Walter Sisulu University and Frere Hospital, East London, South Africa
Muzaffer Tansel Kilinç, MD, FEBU Konya City Hospital, Konya, Turkey
Thomas F Monaghan, MD, PhD University of Texas Southwestern Medical Center, Dallas, TX, USA
Esther García Rojo, MBBS Hospital Universitario HM Sanchinarro, Madrid, Spain
Alan Wein, MD Desai Sethi Urology Institute, University of Miami, Miami, FL and University of Pennsylvania, Philadelphia, PA, USA
Urological Technology
Nithesh Naik, BE, Mtech Manipal Institute of Technology, Manipal, India
Paediatric Urology
Aniruddh Deshpande, MBBS, MCh, AFRACMA, PhD, FRACS Children's Hospital at Westmead, Sydney, Australia
Kiarash Taghavi, MBChB, PGDipSurgAnat, DipPaeds, GCertClinTeach, CHIA Monash Children’s Hospital, Melbourne, Australia
Editorial Review Board
Elia Abou Chawareb, MD Department of Urology, University of California, Irvine, CA, USA
Ramy Abou Ghayda, MD MHA MPH MBA University Hospitals, Case Western Reserve University, Cleveland, Ohio
Ased Ali, B.Sc.(Hons), MB.ChB, PhD, FRCS Department of Urology, Mid Yorkshire Teaching NHS Trust, Wakefield, UK
Aykut BASER, MD, FEBU Bandirma Onyedi Eylul University, Balikesir, Türkiye
Arnab Basu ,MD, MPH, FACP O’Neal Comprehensive Cancer Center, Birmingham, AL, US
Francesco Pio Bizzarri, MD, MSc Isola Tiberina-Gemelli Isola Hospital, Catholic University Medical School, Rome, Italy
Raevti Bole, MD Cleveland Clinic, Cleveland, OH, USA
Emre Bulbul, MD Trabzon Vakfikebir State Hospital, Turkey
Andrea Crafa, MD University of Catania, Catania, Italy
José Arnaldo Shiomi da Cruz, MD, PhD, MBA University of São Paulo, São Paulo, Brazil
Minh-Tung Do ,MD,PhD Hai Phong University of Medicine and Pharmacy, Hai Phong City, Viet Nam
Adel Elatriesy ,MD, MSc, PhD (Urol), FRCS Al-Azhar university, Cairo, Egypt
Golena Fernandez Moncaleano, MD University of Michigan, Ann Arbor, MI, USA
Nazario Foschi Fondazione Policlinico Universitario Agostino Gemelli- IRCCS, Roma, Italy
Cahyani Gita Ambarsari, MD Universitas Indonesia, Jakarta, Indonesia & Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Paul Gravestock, BM BS, MPhys, PGCert Freeman Hospital, Newcastle upon Tyne, UK
Marilena Gubbiotti, MD. Ph.D anta Maria la Gruccia Hospital, Montevarchi (Arezzo), Italy
Kevin Kayvan Zarrabi, MD, MS, FACP Sidney Kimmel Cancer Center, Jefferson Medical College, Philadelphia, PA, USA
Zhi-Bin Ke, MD Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Diomidis Kozyrakis, MD, FEBU "Konstantopouleio-Patision" General Hospital of Nea Ionia, Attiki, Greece
Angus Luk, MBChB, FRCS Freeman Hospital, Newcastle-upon-Tyne, UK
Kumar Madhavan, MBBS, MS, MCh, MRCS, FRCS (Urol) All India Institute of Medical Sciences, Bhopal, India
Stefano Moretto ,MD Humanitas Clinical and Research Institute IRCCS, Rozzano, Milan, Italy
Prashant Motiram Mulawkar, MS Surgery, DNB Surgery, MCh Urology, DNB Urology, ChM Urology Tirthankar Superspeciality Hospital, Akola, Maharashtra, India
Carlotta Nedbal, MD Urology Unit, ASST Fatebenefratelli Sacco, Milan, Italy
Christopher Netsch, MD, FEBU Asklepios Hospital Barmbek, Hamburg, Germany
Sarah Marie Norton, MB, BCh, BAO, BSc, MSc, FRCSI Department of Urology, University Hospital Limerick, Ireland
Luca Orecchia, MD Università Tor Vergata, Rome, Italy
Shiv Kumar Pandian, MS, MD, FRCS North Middlesex University Hospital NHS Trust, London
Mohamed Javid Raja Iyub Miami Cancer Institute, Miami, FL, USA
Cagri Akin Sekerci, MD Marmara University, Turkey
Caio Suartz, MD Urology department, Northern Ontario School of Medicine University, Thunder Bay, ON, Canada
Raveen Syan, MD Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA
Octavian Sabin Tataru, MD, PhD George Emil Palade University of Medicine, Pharmacy, Sciences and Technology, Romania
Mustafa Zafer Temiz, MD, PhD, FEBU Department of Urology, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul, Turkiye
Tuan Thanh Nguyen, MD, MS University of Medicine and Pharmacy Ho Chi Minh City, Ho Chi Minh City, Vietnam
Neeraja Tillu ,MBBS, MS, MCh Urology Icahn School of Medicine at Mount Sinai Hospital, New York, US
Emre Tokuc, MD, FEBU University of Health Sciences, Haydarpasa Numune SUAM, Istanbul, Turkiye
Mudassir Wani, MRCS; M.Ch Urology University Hospital Of Wales, Cardiff, UK
  • Clarivate Analytics: Current Contents - Clinical Medicine
  • Directory of Open Access Journals (DOAJ)
  • ProQuest
  • PubMed: PubMed Central (PMC)
  • Scopus
  • Web of Science: Science Citation Index Expanded (SCIE)
  • Manuscript Submission Guidelines: Therapeutic Advances in Urology

    This Journal is a member of the Committee on Publication Ethics.

    This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

    All articles are listed on PubMed.

    Please read the guidelines below then visit the Journal’s submission site http://mc.manuscriptcentral.com/tau to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.

    Only manuscripts of sufficient quality that meet the aims and scope of Therapeutic Advances in Urology will be reviewed.

    There are no fees payable to submit or publish in this journal.

    As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you. 

    1. What do we publish?
      1.1 Aims & Scope
      1.2 Article types
      1.3 Writing your paper
    2. Editorial policies
      2.1 Peer review policy
      2.2 Authorship
      2.3 Acknowledgements
      2.4 Funding
      2.5 Declaration of conflicting interests
      2.6 Research ethics and patient consent
      2.7 Clinical trials
      2.8 Reporting guidelines
    3. Publishing policies
      3.1 Publication ethics
      3.2 Contributor's publishing agreement
      3.3 Open access and author archiving
    4. Preparing your manuscript
      4.1 Formatting
      4.2 Artwork, figures and other graphics
      4.3 Supplementary material
      4.4 Reference style
      4.5 English language editing services
    5. Submitting your manuscript
      5.1 ORCID
      5.2 Information required for completing your submission
      5.3 Permissions
    6. On acceptance and publication
      6.1 SAGE Production
      6.2 Online First publication
      6.3 Access to your published article
      6.4 Promoting your article
    7. Further information

    1. What do we publish?

    1.1 Aims & Scope

    Before submitting your manuscript to Therapeutic Advances in Urology, please ensure you have read the Aims & Scope.

    1.2 Article Types

    Therapeutic Advances in Urology considers the following kinds of article for publication:

      1. Original Articles. The Editors will consider preclinical, interventional and observational studies with clearly stated aims, well-reported methodology (including main outcome measures) and results, and a discussion of the results in the context of the published literature. 
      2. Review Articles. These manuscripts are usually commissioned by the Editors, but the following types of high-quality review will be considered:  
        (a) General reviews that provide a synthesis of an area that fits within the aims and scope of the journal; 
        (b) Perspective reviews – review articles that address important new areas of general interest and afford the author the opportunity to present a forward-looking perspective on the topic; 
        (c) Drug reviews – review articles focusing on the available evidence for the use of a particular drug or combination therapy.
      3. Systematic Reviews – these should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 2.8). 
      4. Meta-analyses – these should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 2.8). 
      5. Case Reports – these structured reports should describe an unusual case and include a full review of the pertinent literature and a section on implications for clinical care. 
      6. Case Series – these descriptive structured reports (which do not involve formal hypotheses or pre-specified methodology or analyses) of a small group of patients should include a full review of the pertinent literature and a section on implications for clinical care. 
      7. Study Protocols – these can be for forthcoming or ongoing research. Information on trial registration (where applicable) and ethics approval should be included in the manuscript.
      8. Letters to the Editor – these brief opinion pieces should be as concise as possible, usually no more than 1000 words.

    The journal considers the results of rigorous, well-designed studies that demonstrate “no effect” or that fail to replicate previous work (“negative data”) as important to the advancement of science. Therapeutic Advances in Urology welcomes short reports on null or negative results as long as the papers are based on strong hypothesis testing.

    1.3 Writing your paper

    The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.

    1.3.1 Make your article discoverable

    When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online.

    Back to top

    2. Editorial policies

    2.1 Peer review policy

    The journal's policy is to obtain at least two independent reviews of each article. Therapeutic Advances in Urology operates a conventional single-blind reviewing policy in which the reviewer's name is always concealed from the submitting author.  Referees will be encouraged to provide substantive, constructive reviews that provide suggestions for improving the work and distinguish between mandatory and non-mandatory recommendations.  All manuscripts accepted for publication are subject to editing for presentation, style and grammar. Any major redrafting is agreed with the author but the Editor's decision on the text is final.

    As part of the submission process you will be asked to provide the names of 3 peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:

      • The reviewer should have no prior knowledge of your submission
      • The reviewer should not have recently collaborated with any of the authors
      • Reviewer nominees from the same institution as any of the authors are not permitted

    You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).

    Please note that the Editors are not obliged to invite/reject any recommended/opposed reviewers to assess your manuscript.

    The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.

    2.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

    The list of authors should include all those who can legitimately claim authorship. This is all those who:

      1. Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
      2. Drafted the article or revised it critically for important intellectual content,
      3. Approved the version to be published,
      4. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

    2.3 Acknowledgements

    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

    2.3.1 Writing assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.

    2.4 Funding

    Therapeutic Advances in Urology requires all authors to acknowledge their funding in a consistent fashion under a separate heading.  Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. 

    2.5 Declaration of conflicting interests

    It is the policy of Therapeutic Advances in Urology to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations here.

    2.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

    For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

    All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.

    2.7 Clinical trials

    Therapeutic Advances in Urology endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be included at the end of the abstract.

    2.8 Reporting guidelines

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

    Back to top

    3. Publishing Policies

    3.1 Publication ethics

    SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.

    3.1.1 Plagiarism

    Therapeutic Advances in Urology and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    3.1.2 Prior publication

    If material has been previously published it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.

    3.2 Contributor's publishing agreement

    Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit the SAGE Author Gateway.

    3.3 Open access and author archiving

    Therapeutic Advances in Urology offers optional open access publishing via the SAGE Choice programme. For more information please visit the SAGE Choice website. For information on funding body compliance, and depositing your article in repositories, please visit SAGE Publishing Policies on our Journal Author Gateway.

    Back to top

    4. Preparing your manuscript for submission

    4.1 Formatting

    The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

    4.2 Artwork, figures and other graphics

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.  

    4.3 Supplementary material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.

    4.4 Reference style

    Therapeutic Advances in Urology adheres to the SAGE Vancouver reference style. View the SAGE Vancouver guidelines to ensure your manuscript conforms to this reference style.

    If you use EndNote or Zotero to manage references, you can download the appropriate output style file to help format your references quickly.

    EndNote: here
    Zotero: here

    4.5 English language editing services

    Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.

    Back to top

    5. Submitting your manuscript

    Therapeutic Advances in Urology is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit http://mc.manuscriptcentral.com/tau to login and submit your article online.

    IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created.  For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

    5.1 ORCID

    As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a persistent digital identifier that distinguishes researchers from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities ensuring that their work is recognised.

    We encourage all authors to add their ORCIDs to their SAGE Track accounts and include their ORCIDs as part of the submission process. If you don’t already have one you can create one here.

    5.2 Information required for completing your submission

    You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

    5.3 Permissions

    Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway.

    Back to top

    6. On acceptance and publication

    6.1 SAGE Production

    Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly.  Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.

    6.2 Online First publication

    Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the SAGE Journals help page for more details, including how to cite Online First articles.

    6.3 Access to your published article

    SAGE provides authors with online access to their final article.

    6.4 Promoting your article

    Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximise your article’s impact with Kudos

    Back to top

    7. Further information

    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Therapeutic Advances in Urology editorial office as follows:

    urology@sagepub.co.uk

    For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:

    Commercial Sales Team, London, UK
    Tel: +44 20 7336 1205
    Email: reprints@sagepub.co.uk